linjc16/ctgov huggingface dataset:
The Effect of Synching Prescription Refills on Adherence

Study Overview
=================
Brief Summary
-----------------
To determine the effect of synchronizing a patient's prescription refill schedule on medication adherence. The targeted population is Humana members who are currently taking 2 or more Stars medications (hypertension, hypercholesterolemia, diabetes) and are current customers of RightSource. Participants will be randomized to one of two groups. Group one will be usual care and group two will be the Rx synchronization group.

Official Title
-----------------
A Randomized Controlled Trial to Test a Synchronized Prescription Refill Program to Improve Medication Adherence

Conditions
-----------------
Hypertension, Hypercholesterolemia, Diabetes, Medication Adherence

Intervention / Treatment
-----------------
* Behavioral: Refill synch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Humana members who are currently taking 2 or more Stars medications (hypertension, hypercholesterolemia, diabetes) and are current customers of RightSource. Exclusion Criteria: under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Refill synch<br>Participants in this group will have their medication refill schedule synchronized. | Behavioral: Refill synch<br> <br> |
| No Intervention: Control<br>Participants in this arm will receive usual care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure |  | 6 months and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use. |  | 6 and 12 months |
Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo

Study Overview
=================
Brief Summary
-----------------
This is a retrospective analysis and description of the preferred diagnostic and treatment methods employed on GIST on the Region of Coquimbo from 2003 to 2008.

Official Title
-----------------
Outcomes of Surgical Treatment of Gastrointestinal Stromal Tumors in the IV Region of Chile

Conditions
-----------------
Gastrointestinal Stromal Tumors

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All operated patients with GIST Positive immunohistochemistry Exclusion Criteria: Patients with GIST not operated Patients with GIST operated on but without immunohistochemistry

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GIST<br>GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum | Other: Observation<br>* Not applied<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients Who Survived | The outcomes were measured through follow-up visits of the patients to the out-patient clinic of our institution at 15 days, 1 month, 3 months, 6 months, 1 year, and after that, every year after the surgical treatment. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GIST
Brillant Blue Versus Indocyanine Green for Macular Hole Surgery

Study Overview
=================
Brief Summary
-----------------
Macular Hole Surgery with two different Dyes

Official Title
-----------------
Membranepeeling With Brillant Blue Versus Membranepeeling With Indocyanine Green for Patients With Idiopathic Macular Holes.

Conditions
-----------------
Idiopathic Macular Holes

Intervention / Treatment
-----------------
* Procedure: Brillant Blue
* Procedure: Indocyanine Green


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic stage 3 and 4 macular holes Stage 2 macular holes, followed up for at least 6 months Pseudophakic and phakic eyes Age over 60 years Exclusion Criteria: Traumatic macular holes Secondary macular holes Severe ocular diseases

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br>Brillant Blue | Procedure: Brillant Blue<br>* Membrane Peeling with Brillant Blue<br>|
| Active Comparator: Group 2<br>Indocyanine Green | Procedure: Indocyanine Green<br>* Membrane Peeling with indocyanine Green<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macular Hole Closure Rate |  | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity Microperimetry Optical Coherence Tomography |  | 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macular hole surgery, membranepeeling, closure rate, vitreoretinal dyes
Pink and White Esthetic Scores of Polymer-infiltrated-ceramic-network and Lithium Disilicate Implant Hybrid Abutment Crowns

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the effect of polymer-infiltrated-ceramic-network hybrid ceramic on pink and white esthetics in comparison with lithium disilicate. The research hypothesis is that there will be comparable clinical performance results between polymer-infiltrated-ceramic-network and lithium disilicate hybrid abutment crowns.

Official Title
-----------------
Pink and White Esthetic Scores of Polymer-infiltrated-ceramic-network and Lithium Disilicate Implant Hybrid Abutment Crowns: Randomized Clinical Trial

Conditions
-----------------
Dental Implants

Intervention / Treatment
-----------------
* Other: PICN (VITA Enamic) hybrid abutment crown
* Other: Lithium disilicate (IPS e.max) hybrid abutment crown


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Literate, capable of reading and signing the informed consent document Healthy, free from or with controlled systemic disease With acceptable oral health to support implant restorations With good bone quality and quantity Cooperative, accepting follow up and maintenance sessions Having single missing tooth in esthetic zone Exclusion Criteria: Under 18 years old Illiterate, unable of comprehending or signing the informed consent document Unhealthy with uncontrolled systemic disease Pregnancy With unfavorable oral state that might affect implant procedure and restoration Uncooperative, not willing to return for follow up visits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: IPS e.max hybrid abutment crown<br> | Other: Lithium disilicate (IPS e.max) hybrid abutment crown<br>* Glass ceramic<br>|
| Experimental: VITA Enamic hybrid abutment crown<br> | Other: PICN (VITA Enamic) hybrid abutment crown<br>* Hybrid ceramic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pink Esthetic Score (PES) | Pink esthetics | 6 months | 
| White Esthetic Score (WES) | White esthetics | 6 months |
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis

Study Overview
=================
Brief Summary
-----------------
Open label study to evaluate the efficacy of CURE-EX device in the treatment of onychomycosis.

Detailed Description
-----------------
Each affected nail will be treated twice daily for 24-30 weeks. Efficacy will be evaluated by measuring the growth of healthy nail.

Official Title
-----------------
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis

Conditions
-----------------
Onychomycosis

Intervention / Treatment
-----------------
* Device: CURE-EX device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects diagnosed with clinical and mycological onychomycosis (by culture and smear). Subjects did not receive topical antifungal treatment during the 14 days prior to commencing the study. Subjects did not receive any systemic antifungal treatment during the 3 months prior to the start of the study. Exclusion Criteria: lunula infected with onychomycosis. Pregnant or breast feeding female.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CURE-EX device<br>twice daily treatment with CURE-EX device for 24-30 weeks | Device: CURE-EX device<br>* Treatment with CURE-EX device twice daily for 24-30 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nail cure as measured by measured by length of healthy nail of at least 5 mm | Cure measured by length of healthy nail of at least 5 mm | 24-30 weeks | 
| Nail cure as measured by culture and smear | Nail culture and smear | 24-30 weeks |
Demonstration Of A Next Generation PET CT System

Study Overview
=================
Brief Summary
-----------------
The intent of this evaluation is to obtain user feedback on device performance, user preference, image quality, workflow, and new device features, a necessary part of product development. This study will also help to inform protocol development in reducing both scan time and/or radiologic tracer dose. The goal of this study is to collect a library of image data from the hybrid PET/CT system to be used for evaluation and optimization of the image quality of the system in a clinical setting and as comparison with the standard of care hybrid PET/CT system, Discovery MI 25m (DMI5R).

Official Title
-----------------
Demonstration Of A Next Generation PET CT System (OMNI dBGO)

Conditions
-----------------
Oncology

Intervention / Treatment
-----------------
* Device: Additional PET/CT Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult, who is at least 18 years of age; A clinical indication for PET/CT examination according to current clinical practice standards; Able and willing to provide informed consent for participation in this study Exclusion Criteria: Diabetic patient with a glucose level ≥ 150 mg/dl at the time of the exam (for FDG) or, Known to be pregnant or breastfeeding (the investigational site will follow their standard practice of verifying for women of childbearing age. No study specific pregnancy test will be performed for this study); or, Previously enrolled in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: OMNI PET/CT scan first<br> | Device: Additional PET/CT Scan<br>* The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.<br>|
| Other: DMI PET/CT scan first<br> | Device: Additional PET/CT Scan<br>* The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation- Likert Scale | The primary endpoints of this study are completed image evaluation using a 1 point Likert Scale of the OMNI PET/CT system including analysis, reading, and scoring utilizing a Likert Scale, by three (3) qualified Nuclear Medicine physicians. | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Data Collection | PET/CT Image collection | through study completion, an average of 1 year |
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma

Study Overview
=================
Brief Summary
-----------------
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma

Detailed Description
-----------------
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.

Official Title
-----------------
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma

Conditions
-----------------
Uveal Melanoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with metastatic uveal melanoma Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment Exclusion Criteria: Antecedent of another evolutionary tumor pathology
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate Data collection of the efficacity of PD-1 inhibitors | Description of Response rate | December 2019 | 
| Progression Free Survival Data collection of the efficacity of PD-1 inhibitors | Description of PFS (Progression Free Survival) | December 2019 | 
| Global Survival Data collection of the efficacity of PD-1 inhibitors | Description of Global Survival | December 2019 | 
| Stability Data collection of the efficacity of PD-1 inhibitors | Description of Stability at 6 months | December 2019 | 
| Objective response Data collection of the efficacity of PD-1 inhibitors | Description of Objective response | December 2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exploration of PD-1 inhibitors biomarkers | The study of PD-1 inhibitors biomarkers could be useful to identify a group of patients whose the molecules are most activated and then for futures studies. | December 2019 |
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the comfort of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension

Official Title
-----------------
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Conditions
-----------------
Open-angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Brinzolamide/Timolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults of either sex and any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) Exclusion Criteria: Under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Brinzolamide/Timolol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular discomfort |  |  |
Identification of Corticomedullary Differentiation Along Different Stage of Pregnancy

Study Overview
=================
Brief Summary
-----------------
Corticomedullary differentiation (CMD) abnormality (absent/reversed) is a parameter that can indicate possible nephropathy. The evolution of CMD across gestation had not been well established. Devrendt et al demonstrated the presence of CMD in all fetuses older then 20 weeks. In our study we would like to determine the exact timing of it's sonographic visualisation. This is a prospective study recruiting women between 14-24 week gestation during routine ultrasound screening. A midsagittal image of each kidney will be taken by a single sonographer and examined for the presence of the CMD by two other sonographers blinded to gestational age.

Conditions
-----------------
Nephropathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women 14-24 weeks singleton pregnancy Appropriate for gestational age fetuses well dated pregnancy Exclusion Criteria: family history of renal disease small /large for gestational age fetuses known structural anomalies unknown dating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CMD presence |  | A single exam for each participent. The photos will be reviewed within up to 6 month from examination date |
Analgesia for Clavicular Fracture and Surgery

Study Overview
=================
Brief Summary
-----------------
Compared efficacy of ultrasound-guided combined interscalene-cervical plexus versus combined supraclavicular-cervical plexus block for surgical anesthesia in clavicular fractures.

Detailed Description
-----------------
The primary objective of this study was to compare the effectiveness of ultrasound-guided combined interscalene-cervical plexus versus combined supraclavicular-cervical plexus block for surgical anesthesia in clavicular fractures.The hypothesis of this study was that the supraclavicular-cervical plexus block could provide better anesthesia with less anesthesia related complications.

Official Title
-----------------
Ultrasound-Guided Combined Interscalene-Cervical Plexus Versus Combined Supraclavicular-Cervical Plexus Block for Surgical Anesthesia in Clavicular Fractures: A Retrospective Observational Study

Conditions
-----------------
Clavicular Fractures

Intervention / Treatment
-----------------
* Procedure: Interscalene-Cervical Plexus Block
* Procedure: Supraclavicular-Cervical Plexus Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Surgery of the clavicular fractures under combined cervical plexus plus brachial plexus block Urgent or planned surgery Exclusion Criteria: Refused to sign informed consent Pregnant women Allergic to the local anesthetic

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Interscalene-Cervical Plexus Block<br>Ultrasound-Guided Combined Interscalene-Cervical Plexus Block | Procedure: Interscalene-Cervical Plexus Block<br>* Ultrasound-Guided Combined Interscalene-Cervical Plexus Block<br>|
| Supraclavicular-Cervical Plexus Block<br>Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block | Procedure: Supraclavicular-Cervical Plexus Block<br>* Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Block success rate | Sensory blockade was assessed using the pinprick test at the surgery site | At time 15 minutes after the block | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute complications | Number of participants with phrenic nerve palsy | At the end of surgery immediately | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Combined Interscalene-Cervical Plexus Block, Combined Supraclavicular-Cervical Plexus Block